1-甲基-3-[(4-甲基苯甲酰)氨基]脲 | 129521-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-3-[(4-甲基苯甲酰)氨基]脲
• 英文名称: N-methyl-2-(4-methylbenzoyl)-hydrazinecarboxamide
• 英文别名: 1-Methyl-3-[(4-methylbenzoyl)amino]urea
• CAS: 129521-45-5
• 化学式: C₁₀H₁₃N₃O₂
• mdl: MFCD00027436
• 分子量: 207.232
• InChiKey: WHQSWNPBJRLDQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  1-甲基-3-[(4-甲基苯甲酰)氨基]脲 在 sodium hydroxide 作用下， 反应 23.0h， 以78%的产率得到3H-1,2,4-Triazol-3-one, 2,4-dihydro-4-methyl-5-(4-methylphenyl)-
  参考文献：
  名称：

  2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents

  摘要：

  A series of 5-aryl-2,4-dihydro-3H-1,2,4-triazol-3-ones was evaluated for anticonvulsant activity. In general the members of this series were prepared by the alkaline cyclization of 1-aroyl-4-alkylsemicarbazides. The resulting 2-unsubstituted 3H-1,2,4-triazol-3-ones were then alkylated, yielding 2,4-dialkyl-3H-1,2,4-triazol-3-ones. Approximately one-third of the compounds examined exhibited activity against both maximal electroshock- and pentylenetetrazole-induced seizures in mice. Receptor-binding studies suggest that this activity was not a consequence of activity at either benzodiazepine or NMDA-type glutamate receptors. From this series, compound 45 was selected for further evaluation where it was also found to be active against 3-mercaptopropionic acid, bicuculline, and quinolinic acid induced seizures in mice. In addition, 45 also protected gerbils from hippocampal neuronal degeneration produced by either hypoxia or intrastriatal quinolinic acid injection.

  DOI：

  10.1021/jm00172a015
• 作为产物：
  描述：

  异氰酸甲酯 、 对甲苯甲酰肼 以 四氢呋喃 为溶剂， 反应 17.0h， 以86%的产率得到1-甲基-3-[(4-甲基苯甲酰)氨基]脲
  参考文献：
  名称：

  2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents

  摘要：

  A series of 5-aryl-2,4-dihydro-3H-1,2,4-triazol-3-ones was evaluated for anticonvulsant activity. In general the members of this series were prepared by the alkaline cyclization of 1-aroyl-4-alkylsemicarbazides. The resulting 2-unsubstituted 3H-1,2,4-triazol-3-ones were then alkylated, yielding 2,4-dialkyl-3H-1,2,4-triazol-3-ones. Approximately one-third of the compounds examined exhibited activity against both maximal electroshock- and pentylenetetrazole-induced seizures in mice. Receptor-binding studies suggest that this activity was not a consequence of activity at either benzodiazepine or NMDA-type glutamate receptors. From this series, compound 45 was selected for further evaluation where it was also found to be active against 3-mercaptopropionic acid, bicuculline, and quinolinic acid induced seizures in mice. In addition, 45 also protected gerbils from hippocampal neuronal degeneration produced by either hypoxia or intrastriatal quinolinic acid injection.

  DOI：

  10.1021/jm00172a015

文献信息

• Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors
  申请人：Meier Heinrich

  公开号：US20090312381A1

  公开（公告）日：2009-12-17

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• 3-Aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20080113984A1

  公开（公告）日：2008-05-15

  Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds thereof, represented by the Formula I: wherein Ar 1 , Ar 2 , and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及公开的3-芳基-6-芳基-7H-[1,2,4]三唑并[3,4-b][1,3,4]噻二唑及其相关化合物，其由公式I表示：其中Ar1、Ar2和X在此定义。本发明涉及发现具有公式I的化合物是caspase激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在各种临床情况下发生异常细胞的无控制生长和扩散的细胞死亡。
• Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08084481B2

  公开（公告）日：2011-12-27

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，它们的单独或组合使用用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。
• SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
  申请人：Meier Heinrich

  公开号：US20130005704A1

  公开（公告）日：2013-01-03

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新型取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，其单独或联合用于治疗和/或预防疾病的用途以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study
  作者：Neto-Honorius Houngbedji、Šárka Štěpánková、Václav Pflégr、Katarína Svrčková、Markéta Švarcová、Jarmila Vinšová、Martin Krátký

  DOI：10.3390/ph16020172

  日期：——

  tridecylamine. The compounds were evaluated for the inhibition of AChE and BChE using Ellman’s spectrophotometric method. Most of the derivatives showed the dual inhibition of both enzymes with IC50 values of 44–100 µM for AChE and from 22 µM for BChE. In general, the carboxamides inhibited AChE more strongly. A large number of the compounds showed better or quite comparable inhibition of cholinesterases

  根据之前的报道，新型2-苯甲酰肼-1-甲酰胺被设计为乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE）的潜在抑制剂。这些酶的抑制剂有许多临床应用。以市售或自制的酰肼和异氰酸酯为原料，通过三种方法制备了N-甲基或十三烷基修饰的2-（取代苯甲酰基）肼-1-甲酰胺。对于甲基衍生物，使用N-琥珀酰亚胺基N-甲基氨基甲酸酯或通过Curtius重排制备异氰酸甲酯。通过库尔蒂斯重排或由三光气和十三胺再次合成十三烷基异氰酸酯。使用埃尔曼分光光度法评估化合物对 AChE 和 BChE 的抑制作用。大多数衍生物表现出对两种酶的双重抑制作用，AChE 的 IC50 值为 44–100 µM，BChE 的 IC50 值为 22 µM。一般来说，甲酰胺类药物对 AChE 的抑制作用更强。许多化合物在体外表现出比卡巴拉汀更好或相当相当的胆碱酯酶抑制作用。进行分子对接以研究化合物的可能构象及其与目标酶的相互作用。在 AChE